What is DRUG's current stock price?

DRUG (Bright Minds Biosciences Inc.) is currently trading at $83.50 with a market cap of $648.1M.

What sector is Bright Minds Biosciences Inc. in?

Bright Minds Biosciences Inc. (DRUG) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is DRUG a good stock to buy?

Analysts have a Buy consensus on DRUG with a price target of $164.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

DRUG Bright Minds Biosciences Inc.

Healthcare

$83.50+0.31%ClosedMarket Cap: $648.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.62

P/S

0.00

EV/EBITDA

-18.95

DCF Value

$8.58

FCF Yield

-2.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-20.7%

ROA

-8.8%

ROIC

-10.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$0.00	$-10.6M	$—
Q1 null	$0.00	$-7.6M	$—
Q4 null	$0.00	$-4.1M	$—
FY null	$0.00	$-12.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$164.33

Target (Median)

$147.00

Target Range

$126.00 - $220.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Piper SandlerOverweight

2026-05-20

BTIGBuy

2026-03-30

HC Wainwright & Co.Buy

2026-03-04

BTIGBuy

2026-02-17

BTIGBuy

2026-01-07

Trading Activity

Insider Trades

View All

Cormorant Asset Management, LPother: Former 10% Owner

SellThu Apr 30

Cormorant Asset Management, LP10 percent owner

BuyWed Nov 06

Cormorant Asset Management, LP10 percent owner

BuyThu Oct 17

Cormorant Asset Management, LP10 percent owner

BuyThu Oct 17

Cormorant Asset Management, LP10 percent owner

BuyThu Oct 17

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.19

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Peers

ALT